Press Release

Rarecells Announces New Clinical Data Showing Superior Sensitivity and Tumor Heterogeneity Detection by Synergistic Combination of ctDNA and ISET® CTC-DNA in Patients with Early-Stage Lung Cancer

Leave a Comment / Press Release /

NEW YORK and PARIS, September 9th, 2025 (GLOBE NEWSWIRE) – Rarecells, a pioneer in liquid biopsy technologies, today presented new data (poster EP.06.64) at the IASLC 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain, from its BioMolCTC Trial conducted in collaboration with Prof. Filippo Lococo’s team at Policlinico Gemelli in Rome. Circulating Tumor […]

Rarecells Announces New Clinical Data Showing Superior Sensitivity and Tumor Heterogeneity Detection by Synergistic Combination of ctDNA and ISET® CTC-DNA in Patients with Early-Stage Lung Cancer Read More »

Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board

Leave a Comment / Press Release /

NEW YORK, NY and PARIS, FRANCE – June 18, 2025 Rarecells, Inc., a leader in liquid biopsy technology, is pleased to announce the appointment of Dr. Rita Shaknovich to its Scientific Advisory Board. Dr. Shaknovich brings over 20 years of leadership experience across private industry and academia. She has a distinguished track record of building

Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board Read More »

Press release : Rarecells, Inc. announces successful Series A funding, reaching $13 Million raised to develop Liquid Biopsy Early Cancer Detection Tests

Leave a Comment / Press Release /

NEW YORK and PARIS, Dec. 9, 2021  — Rarecells, Inc., an innovative Liquid Biopsy company developing non-invasive tests for early cancer diagnosis, announced today the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million. The funds will support the start of laboratory and clinical operations in the United-States focused

Press release : Rarecells, Inc. announces successful Series A funding, reaching $13 Million raised to develop Liquid Biopsy Early Cancer Detection Tests Read More »

Press release : Rarecells, Inc. to fund a clinical study at Columbia University of its ISET® -AML test for early detection of Acute Myeloid Leukemia (AML)

Leave a Comment / Press Release /

New York, November 9th, 2021 — Rarecells, Inc., a healthcare company in the field of liquid biopsy, focused on the development and commercialization of non-invasive tests for early cancer detection, announced today that it has entered into an agreement with Columbia University to fund a clinical study evaluating its ISET® -AML test for early detection

Press release : Rarecells, Inc. to fund a clinical study at Columbia University of its ISET® -AML test for early detection of Acute Myeloid Leukemia (AML) Read More »

Press release : ISET® technology makes Circulating Tumor Cells accessible to target PDAC mutant genes detection in pancreatic cancer with an accuracy demonstrated by a targeted scNGS

Leave a Comment / Press Release /

PARIS, April 6, 2021 /PRNewswire/ — Rarecells Inc., a leading Liquid Biopsy company is pleased to announce the development of an innovative and accurate targeted digital single-cell Next-Generation Sequencing (scNGS) for single-nucleotide variant (SNV) method to detect mutant genes of pancreatic ductal adenocarcinoma (PDAC) circulating tumor cells (CTC) enriched by the ISET® technology.  A peer-reviewed article, published in

Press release : ISET® technology makes Circulating Tumor Cells accessible to target PDAC mutant genes detection in pancreatic cancer with an accuracy demonstrated by a targeted scNGS Read More »

Press release : ISET® test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells

Leave a Comment / Press Release /

We are enthusiastic to share the results of the Professor Karin Ried and researchers of the National Institute of Integrative Medicine (Melbourne, Australia).  PARIS, Oct. 28, 2020 /PRNewswire/ — Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men

Press release : ISET® test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells Read More »

Press release : ISET® technology applied to DLA products from NSCLC patients identified more CTC than other systems

Leave a Comment / Press Release /

We are enthusiastic to share the results of the research conducted by Dr Tamminga from the University of Groningen. ISET Technology applied to DLA products. This research opens a new interesting way to look at the very rare cancer cells in the patient bloodstream.   PARIS, Sept. 24, 2020 /PRNewswire/ — Rarecells Diagnostics (France), a leading liquid biopsy company,

Press release : ISET® technology applied to DLA products from NSCLC patients identified more CTC than other systems Read More »

Visit Rarecells on LinkedIn

Click here to follow
X
Scroll to Top

You're one click away from your download !

Please enter the requested information below and click SEND

No Thanks!

You're one click away from your download !

Please enter the requested information below and click SEND

No Thanks!

You're one click away from your download !

Please enter the requested information below and click SEND

No Thanks!